Recordati has finally sealed a sale. Private equity player CVC Capital Partners said Friday it would drop €3.03 billion—€2.3 billion in cash and €750 million in long-term debt—to pick up the Recordati family’s 51.8% controlling stake in the company.
The agreement follows a Financial Times report that squabbling among members of the Recordati family—who have been weighing a sale since the 2016 death of CEO Giovanni Recordati—might have scuttled a potential deal. Political uncertainty in Italy also gave CVC pause at one point, the FT noted.
Now, though, Recordati has a “great outcome” on its hands, CEO Andrea Recordati—who will stay on as skipper after the deal closes—said in a statement.
“It was important to find a party that would allow Recordati to remain independent, with continuity for management and employees, and accelerate its growth strategy as a leading global consolidator in the pharmaceutical industry,” he said in a statement, adding that he was “personally reinvesting … as I believe in and support Recordati.”
CVC, for its part, is hoping it can expand Recordati’s “very attractive rare disease business” alongside the company’s core business, Cathrin Petty, CVC’s head of EMEA healthcare, said in her own statement.
“We hope that through our expertise and global healthcare network we will help accelerate this growth across orphan and specialty care to build a global leader in the industry,” she said. CVC’s portfolio currently includes Italian generics maker DOC Generici, as well as copycat Alvogen.
Before landing on CVC as a deal partner, Recordati held informal talks with Asian bidders, and private equity firms Bain and Cinven also reportedly took a look at the company. Before selling, though, Recordi put on its buyer’s hat, forking over $300 million to AstraZeneca in exchange for European rights to heart drug Seloken and related combo product Logimax.
By Carly Helfand
Source: Fierce Pharma
Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.
The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.
Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.